Performance Highlights - BeiGene (06160.HK) reported a revenue of 17.518 billion yuan for the first half of the year, a year-on-year increase of 46%; product revenue was 17.36 billion yuan, up 45.8%; net profit was 450 million yuan, turning from loss to profit [2] - Uni-President China (00220.HK) achieved approximately 17.087 billion yuan in revenue for the first half, a year-on-year increase of 10.6%; net profit was about 1.287 billion yuan, up 33.2% [2] - Zhiyu City Technology (09911.HK) announced a positive profit forecast, expecting mid-term revenue of approximately 3.135 to 3.215 billion yuan, a year-on-year increase of about 38.0% to 41.5%; net profit is expected to be around 470 to 510 million yuan, a year-on-year growth of approximately 108.9% to 126.7% [2] Earnings Forecasts - New World Development Company (00086.HK) expects mid-term net profit to increase to no less than 800 million HKD year-on-year [3] - Weizhi Jinkou (02003.HK) anticipates mid-term net profit exceeding 200 million HKD, a significant increase year-on-year [3] - Wing Chan Industrial (01596.HK) forecasts mid-term net profit of approximately 48.7 million HKD, turning from loss to profit [3] - Huaxian Optoelectronics (00334.HK) expects mid-term net profit to exceed 48.8 million HKD, a year-on-year increase of over 600% [3] - Maifushi (02556.HK) predicts mid-term net profit of approximately 31.8 to 41 million HKD, turning from loss to profit [4] - Xinwei Medical-B (06609.HK) expects mid-term net profit to exceed 40 million HKD, turning from loss to profit [5] - China Nuclear Technology (00611.HK) anticipates mid-term net profit growth of over 15% [6] Earnings Warnings - Hongxing Printing Group (00450.HK) expects mid-term net loss of approximately 49 million HKD, a significant increase year-on-year [7] - Zhongyu Land (01224.HK) forecasts mid-term net loss of approximately 40 million HKD, turning from profit to loss [7] - Beihai Group (00701.HK) anticipates mid-term net loss of 36 to 40 million HKD [8] Real Estate Sales Data - China Overseas Development (00688.HK) reported cumulative contract property sales of approximately 132 billion yuan for the first seven months, a year-on-year decrease of 18.3% [9] - Yuexiu Property (00123.HK) achieved cumulative contract sales of approximately 67.506 billion yuan for the first seven months, a year-on-year increase of about 11.7% [9] - Poly Property Group (00119.HK) reported contract sales of approximately 29.5 billion yuan for the first seven months, a year-on-year decrease of 13.49% [10] - China Overseas Hongyang Group (00081.HK) reported cumulative contract sales of 18.649 billion yuan for the first seven months, a year-on-year decrease of 12.2% [10] - Jindi Commercial Real Estate (00535.HK) reported cumulative contract sales of approximately 6.98 billion yuan for the first seven months, a year-on-year decrease of 37.37% [10] - Agile Group (03383.HK) reported pre-sale amount of approximately 5.69 billion yuan for the first seven months [11] - Hongyang Real Estate (01996.HK) reported cumulative contract sales of 3.208 billion yuan for the first seven months, a year-on-year decrease of 41.6% [12] - Zhengrong Real Estate (06158.HK) reported cumulative contract sales of approximately 2.701 billion yuan for the first seven months, a year-on-year decrease of 30.6% [12] - Jingrui Holdings (01862.HK) reported cumulative contract sales of approximately 571 million yuan for the first seven months, a year-on-year decrease of 52.54% [13] Company News - CITIC Securities (06030.HK) reported that its subsidiary, Huaxia Fund, achieved revenue of 4.258 billion yuan and net profit of 1.123 billion yuan in the first half, with assets under management totaling 285.1237 billion yuan [14] - Xinyi International (00732.HK) reported a cumulative operating revenue of approximately 9.566 billion HKD for the first seven months, a year-on-year decrease of about 5.3% [15] - Heng Rui Pharmaceutical (01276.HK) received orphan drug designation from the US FDA for its injection of Rikan Trastuzumab combined with Adebali for gastric cancer or gastroesophageal junction adenocarcinoma indications [15] - Fuhong Hanlin (02696.HK) completed the first patient dosing in a Phase II clinical study of HLX79 injection combined with Hanlikang® for active renal glomerulonephritis in China [15] - China Biopharmaceutical (01177.HK) announced that its self-developed TQ05105 (JAK/ROCK inhibitor) has been included in the breakthrough therapy designation program for the treatment of chronic graft-versus-host disease [15] Buyback Activities - HSBC Holdings (00005.HK) repurchased approximately 1.65 billion HKD worth of about 1.714 million shares at a price of 95.8 to 96.75 HKD [16] - Hang Seng Bank (00011.HK) spent approximately 22.6347 million HKD to repurchase 200,000 shares at a price of 112.8 to 113.6 HKD [17] - Yum China (09987.HK) repurchased approximately 6.264 million HKD worth of 16,800 shares at a price of 369.8 to 376 HKD [17]

Group 1 - The company, Yicheng Industrial (01596.HK), has signed a memorandum of understanding (MOU) regarding a potential acquisition of equity in a target company based in China, specifically in Shijiazhuang, Hebei Province, which is engaged in electricity trading [1] - The target company's subsidiaries are primarily involved in electricity supply and construction businesses, with potential sellers including individuals who are major shareholders of the company [1] - The MOU is effective immediately upon signing and is set to expire on December 31, 2025, during which the company will conduct further due diligence and negotiate transaction terms with potential sellers [1] Group 2 - Yicheng Industrial has announced a positive earnings forecast, expecting a consolidated net profit of 48.7 million yuan for the interim period, indicating a turnaround from a loss to profit [2]

Core Viewpoint - Yicheng Industrial (01596.HK) expects to report a consolidated net profit of approximately RMB 48.7 million for the six months ending June 30, 2025, compared to a consolidated net loss of approximately RMB 42.2 million for the six months ending June 30, 2024, indicating a turnaround of approximately RMB 90.9 million [1] Financial Performance - The improvement in financial performance is attributed to the absence of fair value losses related to trading financial assets and investment losses from the disposal of trading financial assets, as the company disposed of all its holdings in Hong Kong listed securities in 2024, which had incurred losses of approximately RMB 58.1 million for the six months ending June 30, 2024 [1] - The group's gross profit increased by approximately RMB 25.2 million for the six months ending June 30, 2025, driven by the progress of railway project construction and changes in customer structure [1]

翼辰实业(01596)公布，于2025年8月6日，该集团(作为潜在买方)与一家于中华人民共和国成立的公司 (目标公司)的若干登记股东(潜在卖方)就可能买卖目标公司股权订立谅解备忘录。目标公司主要于中国 河北省石家庄市藁城区从事电力买卖业务，其附属公司分别主要从事电力供应及建筑业务。潜在卖方包 括身为该公司控股股东的个人。 ...

Core Viewpoint - The company, Yicheng Industrial (01596), anticipates a significant turnaround in financial performance, projecting a consolidated net profit of approximately RMB 48.7 million for the six months ending June 30, 2025, compared to a consolidated net loss of about RMB 42.2 million for the same period in 2024, indicating a turnaround of approximately RMB 90.9 million [1] Financial Performance - The improvement in financial performance is attributed to the absence of fair value losses related to trading financial assets and investment losses from the disposal of trading financial assets, as the company disposed of all its holdings in Hong Kong-listed securities in 2024, which had incurred losses of approximately RMB 58.1 million for the six months ending June 30, 2024 [1] - The gross profit for the six months ending June 30, 2025, is expected to increase by approximately RMB 25.2 million, driven by the progress of railway project construction and changes in customer structure [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 Hebei Yichen Industrial Group Corporation Limited* 河北翼辰實業集團股份有限公司 （於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司） 諒解備忘錄並不構成訂約方就建議交易事項或其條款或安排或訂立任何正式 協 議 之 具 法 律 約 束 力 協 議。除 上 文 所 述 者 外，諒 解 備 忘 錄 的 其 他 條 文（如 有 關 盡 職 審 查 權 利、保 密、費 用 及 諒 解 備 忘 錄 期 限 之 條 文）對訂約各方均具法律約 束 力。 – 1 – （股 份 代 號：1596） 自願性公告 有關可能收購電力業務權益之 諒解備忘錄 本自願性公告由河北翼辰實業集團股份有限公司（「本公司」）作 出，旨 在 向 本 公 司股東（「股 東」）及 潛 在 投 資 者 提 供 有 關 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 Hebei Yichen Industrial Group Corporation Limited* 河北翼辰實業集團股份有限公司 （於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司） （股 份 代 號：1596） 正面盈利預告 – 1 – (i) 截 至2025年6月30日止六個月並無確認交易性金融資產相關的公允值變動 虧 損 及 處 置 交 易 性 金 融 資 產 取 得 的 投 資 虧 損，原 因 為 本 公 司 已 於2024年 處 置 持 有 的 全 部 香 港 上 市 公 司 證 券，而 於 截 至2024年6月30日 止 六 個 月，有 關 虧損約為人民幣58.1百 萬 元； (ii) 於截至2025年6月30日止六個月本集團毛利增加約人民幣25.2百 萬 元，主 要 受 鐵 路 項 目 工 程 施 工 進 ...

智通财经APP讯，瑞迪智驱(301596.SZ)发布公告，公司于近日收到股东成都迪英财务咨询中心(有限合 伙)、卓玉清出具的《关于股份减持计划的告知函》，以上股东拟分别减持不超过1.5999%、0.9226%公 司股份。 ...

格隆汇8月5日丨瑞迪智驱(301596.SZ)公布，公司持股5%以上股东成都迪英财务咨询中心(有限合伙)持 有公司股份4,494,000股(占公司总股本的5.8239%)，持股5%以上股东卓玉清直接持有公司股份2,040,850 股、间接持有公司股份2,159,374股(合计持有股份占公司总股本的5.4432%)，计划在减持计划公告披露 之日起15个交易日后的3个月内(即2025年8月27日至2025年11月26日，窗口期除外)以集中竞价交易方 式、大宗交易方式分别减持公司股份不超过1,234,605股、711,906股，拟减持股数占公司总股本的比例 分别为1.5999%、0.9226%。 ...

通过天眼查大数据分析，成都瑞迪智驱科技股份有限公司共对外投资了2家企业，参与招投标项目29 次，知识产权方面有商标信息16条，专利信息146条，此外企业还拥有行政许可38个。 来源：金融界 资金流向方面，今日主力资金净流入3375.53万元，占比成交额12.21%。其中，超大单净流入1916.60万 元、占成交额6.93%，大单净流入1458.93万元、占成交额5.28%，中单净流出流出1035.84万元、占成交 额3.75%，小单净流出2339.69万元、占成交额8.46%。 金融界消息 截至2025年8月4日收盘，瑞迪智驱（301596）报收于91.6元，上涨5.31%，换手率8.8%，成 交量3.05万手，成交金额2.76亿元。 天眼查商业履历信息显示，成都瑞迪智驱科技股份有限公司，成立于2009年，位于成都市，是一家以从 事其他制造业为主的企业。企业注册资本7716.53万人民币，实缴资本4133.8554万人民币。公司法定代 表人为卢晓蓉。 瑞迪智驱最新一期业绩显示，截至2025一季报，公司营业总收入1.39亿元、同比增长6.14%，归属净利 润2353.64万元，同比减少4.68%，扣非净利润22 ...